Aclaris Therapeutics Inc (0H8T.L)

Name: Aclaris Therapeutics Inc Financial Statements
Creator: Quarter Results

Healthcare | Medical Pharmaceuticals

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$1.3M

Net Income

-$19.8M

Operating Margin

-1,755.5%

Free Cash Flow

-$47.1M

Debt / Assets

35.8%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Aclaris Therapeutics Inc (0H8T.L).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	1,295,000	3,299,000	1,777,000	1,455,000
Cost of Revenue	-803,000	538,000	1,850,000	506,000
Gross Profit	2,098,000	2,761,000	-73,000	949,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	5,576,000	4,871,000	5,386,000	6,139,000
Operating Expenses	24,832,000	19,910,000	18,335,000	19,033,000
Operating Income	-22,734,000	-17,149,000	-18,408,000	-18,084,000
Interest Expense	0	0	0	0
Income Before Tax	-19,795,000	-14,614,000	-15,429,000	-15,085,000
Income Tax Expense	0	0	0	0
Net Income	-19,795,000	-14,614,000	-15,429,000	-15,085,000
Per Share
EPS	-0.16	-0.12	-0.13	-0.12
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Aclaris Therapeutics Inc (0H8T.L).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	7,826,000	18,720,000	31,249,000	29,752,000
Cost of Revenue	2,091,000	2,792,000	18,081,000	11,960,000
Gross Profit	5,735,000	15,928,000	13,168,000	17,792,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	21,972,000	22,203,000	31,098,000	25,133,000
Operating Expenses	82,110,000	157,860,000	110,525,000	102,946,000
Operating Income	-76,375,000	-141,932,000	-97,357,000	-85,154,000
Interest Expense	0	0	0	0
Income Before Tax	-64,923,000	-132,065,000	-88,848,000	-86,908,000
Income Tax Expense	0	0	-367,000	0
Net Income	-64,923,000	-132,065,000	-88,481,000	-86,908,000
Per Share
EPS	-0.53	-1.71	-1.27	-1.33
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Aclaris Therapeutics Inc (0H8T.L).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	19,960,000	24,570,000	39,878,000	45,277,000
Short Term Investments	70,791,000	89,024,000	79,228,000	172,294,000
Net Receivables	5,565,000	318,000	298,000	484,000
Inventory	0	0	0	0
Total Current Assets	151,363,000	125,951,000	128,856,000	231,550,000
Property Plant Equipment	0	1,008,000	1,620,000	3,779,000
Goodwill and Intangibles	0	0	269,000	6,973,000
Total Assets	160,460,000	220,327,000	197,405,000	257,958,000
Liabilities
Account Payables	13,158,000	4,690,000	8,878,000	10,351,000
Short Term Debt	551,000	0	426,000	684,000
Total Current Liabilities	28,645,000	31,596,000	30,952,000	21,938,000
Long Term Debt	1,565,000	0	0	0
Total Liabilities	57,378,000	64,773,000	40,226,000	60,337,000
Shareholders Equity
Retained Earnings	-967,784,000	-902,861,000	-770,796,000	-682,315,000
Total Shareholders Equity	103,082,000	155,554,000	157,179,000	197,621,000

Balance sheet annual history for Aclaris Therapeutics Inc (0H8T.L).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	19,960,000	24,570,000	39,878,000	45,277,000
Short Term Investments	70,791,000	89,024,000	79,228,000	172,294,000
Net Receivables	5,565,000	318,000	298,000	484,000
Inventory	0	0	0	0
Total Current Assets	151,363,000	125,951,000	128,856,000	231,550,000
Property Plant Equipment	0	1,008,000	1,620,000	3,779,000
Goodwill and Intangibles	0	0	269,000	6,973,000
Total Assets	160,460,000	220,327,000	197,405,000	257,958,000
Liabilities
Account Payables	13,158,000	4,690,000	8,878,000	10,351,000
Short Term Debt	551,000	0	426,000	684,000
Total Current Liabilities	28,645,000	31,596,000	30,952,000	21,938,000
Long Term Debt	1,565,000	0	0	0
Total Liabilities	57,378,000	64,773,000	40,226,000	60,337,000
Shareholders Equity
Retained Earnings	-967,784,000	-902,861,000	-770,796,000	-682,315,000
Total Shareholders Equity	103,082,000	155,554,000	157,179,000	197,621,000

Cash flow quarterly history for Aclaris Therapeutics Inc (0H8T.L).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-64,923,000	-132,065,000	-88,481,000	-86,908,000
Depreciation & Amortization	454,000	807,000	863,000	797,000
Stock Based Compensation	12,384,000	10,856,000	20,542,000	15,039,000
Change in Working Capital	2,672,000	10,922,000	9,389,000	-1,195,000
Operating Cash Flow	-47,113,000	-20,075,000	-78,325,000	-67,567,000
Investing Activities
Capital Expenditure	-111,000	-121,000	-1,309,000	-605,000
Investments	-111,000	-121,000	-1,309,000	-605,000
Investing Cash Flow	48,365,000	-69,769,000	46,220,000	12,628,000
Financing Activities
Debt Repayment	0	0	0	0
Common Stock Issued/Repurchased	0	74,913,000	26,714,000	72,867,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-5,862,000	74,536,000	26,706,000	72,867,000
Summary
Free Cash Flow	-47,113,000	-20,196,000	-79,634,000	-68,172,000
Net Change in Cash	-4,610,000	-15,308,000	-5,399,000	17,928,000

Cash flow annual history for Aclaris Therapeutics Inc (0H8T.L).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-64,923,000	-132,065,000	-88,481,000	-86,908,000
Depreciation & Amortization	454,000	807,000	863,000	797,000
Stock Based Compensation	12,384,000	10,856,000	20,542,000	15,039,000
Change in Working Capital	2,672,000	10,922,000	9,389,000	-1,195,000
Operating Cash Flow	-47,113,000	-20,075,000	-78,325,000	-67,567,000
Investing Activities
Capital Expenditure	-111,000	-121,000	-1,309,000	-605,000
Investments	-111,000	-121,000	-1,309,000	-605,000
Investing Cash Flow	48,365,000	-69,769,000	46,220,000	12,628,000
Financing Activities
Debt Repayment	0	0	0	0
Common Stock Issued/Repurchased	0	74,913,000	26,714,000	72,867,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-5,862,000	74,536,000	26,706,000	72,867,000
Summary
Free Cash Flow	-47,113,000	-20,196,000	-79,634,000	-68,172,000
Net Change in Cash	-4,610,000	-15,308,000	-5,399,000	17,928,000